Navigation Links
RheumatologyNetwork Presents RA Findings from ACR Annual Meeting
Date:12/3/2013

NORWALK, Conn., Dec. 3, 2013 /PRNewswire/ -- UBM Medica US announces two new videos on RheumatologyNetwork, the leading online community for rheumatologists,  describing startling findings about rheumatoid arthritis, an autoimmune condition that affects about 1.3 million adults in the United States.

Despite dramatic advances in new drugs for rheumatoid arthritis (RA) treatment, according to research presented at the recent American College of Rheumatology annual meeting in San Diego (and recounted in the videos):

  • Many patients continue to experience considerable pain months after treatment with the new biologic drugs has started, even though their doctors may think that treatment has been successful because inflammation has been reduced
  • Urged by national guidelines to begin treatment for rheumatoid arthritis as soon as possible because the new medications are so successful, some doctors run the risk of initiating treatment for patients who would recover spontaneously.

Research from the Karolinska University Hospital in Sweden, described in the video "Big Flaw in RA Treatment Success Record: Remaining Pain" by Karolinska rheumatologist Jon Lampa, tracked records from more than 8000 RA patients and controls in a Swedish database and found that many continued to have pain three months after beginning treatment.  It's important for doctors to track pain as well as inflammation, he says.

Many rheumatologists refer to a "window of opportunity" during which they can begin to treat RA early enough so that it never becomes severe. In the video  "When Does the RA Window of Opportunity Actually Open" by rheumatologist Ellen Sauar Norli MD of the Martina Hanssens Hospital in Gjettem, Norway, the authors try to define the duration of pain and clinical indicators that optimize the likelihood that joint pain actually represents rheumatoid arthritis and not a more transient problem, before rheumatologists initiate treatment with expensive and potentially dangerous drugs.

About UBM Medica US
Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world.. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections.  Headquartered in New York, UBM Connect brings together UBM's healthcare business, UBM Medica US; UBM Canon's advanced design and manufacturing event, online and print brands; UBM Connect New York's catering, cruise shipping, customer management, and fine, specialty and custom chemical communities; and UBM Mexico's concrete show.  For more information, visit www.UBMMedicaUS.com.

About UBM plc
UBM plc is a global events-led marketing services and communications company.  We help businesses do business, bringing the world's buyers and sellers together at events and online, as well as producing and distributing news and specialist content.  Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.

For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.

Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
jason.golden@ubm.com


'/>"/>
SOURCE UBM Medica US
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Burzynski Clinic Presents the Results of a Phase II Study of Antineoplastons in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma at the Congress
2. Ventana presents CareGiver remote support at 2013 DreamForce
3. DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
4. Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
5. Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
6. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
7. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
8. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
9. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
10. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
11. Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):